Quest Diagnostics Incorporated (DGX) Q4 2025 (USD): EPS 2.42 (exp. 2.36), Revenue 2.81bln (exp. 2.75bln), Next FY EPS 10.50-10.70 (exp. 10.42), Next FY Rev. 11.7-11.82bln (exp. 11.38bln)

Quest Diagnostics Incorporated (DGX) Q4 2025 (USD): EPS 2.42 (exp. 2.36), Revenue 2.81bln (exp. 2.75bln), Next FY EPS 10.50-10.70 (exp. 10.42), Next FY Rev. 11.7-11.82bln (exp. 11.38bln)

Quest Diagnostics' Q4 results beat expectations on both EPS and revenue, indicating strong operational performance. The upward guidance for next fiscal year suggests management is optimistic about growth, which may lead to a positive reaction in the stock and potentially enhance sentiment towards the healthcare sector as a whole.